Search clinical trials for: Dipeptidyl-peptidase 4 (DPP-4) inhibitors

Total 2569 results

Novartis

Completed

A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Novartis

Completed

Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers

Healthy

China
National Cancer Institute (NCI)

Active, not recruiting

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Merck Sharp & Dohme LLC

Completed

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Advanced Breast Cancer | Other Solid Tumors
Novartis Pharmaceuticals

Completed

A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Rio de Janeiro State University
Laboratory for Clinical and Experimental Research on Vascular Biology

Completed

Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women

1- Microvascular Function | 2-oxidative Stress | 3-inflammation

Brazil
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Japan
Novartis

Completed

Phase 4 Study in the Elderly Patients With T2DM (GLYCEMIA)

Type 2 Diabetes Mellitus | Elderly

France
Novartis

Completed

A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes

Pre-diabetes

United States
Merck Sharp & Dohme LLC

Completed

Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)

Type 2 Diabetes Mellitus
Mayo Clinic
Novartis Pharmaceuticals

Completed

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
Novartis

Completed

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Type-2 Diabetes

Germany, United States
Novartis

Completed

Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects

Healthy | Type-2 Diabetes

Germany
University Hospital, Toulouse
Novartis Pharmaceuticals; Institute of Molecular Medicine of Rangueil (I2MR); Faculty of Medicine, Toulouse

Completed

Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy (DPPNAC)

Diabetes Mellitus

France
Shinshu University
Kowa Company, Ltd.

Recruiting

Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) (TRUTH-DKD)

T2DM (Type 2 Diabetes Mellitus) | Metformin | SGLT2-Inhibitors

Japan
Royal Devon and Exeter NHS Foundation Trust
NIHR Exeter Clinical Research Facility

Completed

Glucose Response, Excursions And Treatment (GREAT) Study (GREAT)

Type 2 Diabetes

United Kingdom
University of Dundee

Completed

Study of Sulphonylurea Synergy With DPP4 Inhibitors (SSS)

Type 2 Diabetes

United Kingdom
Proteus Digital Health, Inc.

Withdrawn

Proteus Sustained Behavior Change Study

Type 2 Diabetes Mellitus

United States
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Urothelial Carcinoma

China
Kowa Research Institute, Inc.

Completed

Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult Volunteers

Healthy

United States
University of Washington
National Institute of Mental Health (NIMH)

Completed

Mobile Mental Health Apps for Suicide Prevention

Depression | Anxiety | Emotional Regulation

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin

Diabetes Mellitus, Type 2

Germany, Switzerland
Oslo University Hospital
Vestre Viken Hospital Trust; University of Oslo; The Research Council of Norway; University Hospital, Akershus and other collaborators

Recruiting

Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose (DIASA3)

Glucose Metabolism Disorders | Impaired Glucose Tolerance | Insulin Sensitivity

Norway
Centre Hospitalier Universitaire de Besancon
University Hospital, Strasbourg, France; Centre Hospitalier Universitaire de... and other collaborators

Recruiting

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period (PRODIG)

Diabetes | Disorder Related to Renal Transplantation

France
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Diabetes Mellitus, Type 2 | Renal Insufficiency

Spain, Canada, France, Germany, Australia, Costa Rica, Finland, Russian Federation, Argentina, India, Norway, Sweden
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Diabetes Mellitus, Type 2

Spain, Argentina, Russian Federation, Norway, India, Sweden, Finland, France, Canada, Germany, Australia, Costa Rica
Novartis

Completed

Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Switzerland
Novartis Pharmaceuticals

Terminated

Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes (VIDA)

Type 2 Diabetes Mellitus

Mexico
University Hospital, Strasbourg, France
Novartis

Completed

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Haemodialyzed, Type 2 Diabetes

France
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Taiwan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China, Thailand, Philippines, Singapore
JW Pharmaceutical

Completed

A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients (CWP-DIANA-301)

Type 2 Diabetes Mellitus

Korea, Republic of
Lund University

Completed

Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes

Hypoglycemia | Diabetes

Sweden
Institut fur Diabetesforschung, Munich, Germany

Unknown

PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)

Insulin-dependent Gestational Diabetes

Germany
Chromaderm, Inc.

Completed

The Effect of Ruboxistaurin on Small Fiber Function

Diabetic Neuropathy

United States
MicuRx
Worldwide Clinical Trials

Completed

Single Dose and Multiple Dose Escalation Trial of an Oral Formulation of MRX-4

Safety
Maastricht University
Netherlands Brain Foundation

Completed

Roflumilast to Treat Cognitive Sequela After Stroke (ROSTMEMA)

Cerebrovascular Disorders | Functional Recovery | Memory | Drug Intervention

Netherlands
Novartis

Completed

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Thailand
Novartis Pharmaceuticals

Completed

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Type 2 Diabetes

China
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)

Healthy

Egypt
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Untreated Adult Acute Myeloid Leukemia

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

China
G1 Therapeutics, Inc.

Terminated

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Small Cell Lung Cancer

United States, Croatia, Belgium, Slovakia, Bosnia and Herzegovina, North Macedonia, Serbia, Slovenia
Virginia Clinical Research, Inc.
Celgene Corporation

Unknown

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

Lichen Planus

United States
AET Laboratories Private Limited

Completed

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.

Diabetes Mellitus
Novartis Pharmaceuticals

Completed

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Type II Diabetes Mellitus | Congestive Heart Failure

Russian Federation, Singapore, Italy, Czechia, Lithuania, Germany, Guatemala, India, Denmark, Estonia, Slovakia, Romania, Latvia, Greece, Poland
SatRx LLC

Completed

Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

Diabetes Mellitus, Type 2

Russian Federation

3

Subscribe